Presentation is loading. Please wait.

Presentation is loading. Please wait.

Five year results of a randomized Phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma Brian O'Sullivan, Aileen.

Published byChristiana Webster Modified over 8 years ago

Similar presentations

Presentation on theme: "Five year results of a randomized Phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma Brian O'Sullivan, Aileen."— Presentation transcript:

1 Five year results of a randomized Phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma Brian O'Sullivan, Aileen Davis, Robert Turcotte, Robert Bell, Jay Wunder, Charles Catton, Rita Kandel, Alex Hammond, Carolyn Freeman, Marc Isler, Karen Goddard, Pierre Chabot, Dongsheng Tu, Joseph Pater Canadian Sarcoma Group National Cancer Institute of Canada, Clinical Trials Group / Groupe des assais clinique

2 SR-2 Trial (NCIC CTG / CSG) Extremity Soft tissue sarcoma (appropriate histology) No chemotherapy Any T,N0,M0 Any grade Combined modality treatment needed: → Surgical and Radiation Oncology opinion Stratification at 10 cm cut-point R A N D O M IZ A TI O N Pre-op RT 50 Gy in 25 fractions Phase 2 to 66 Gy, if margins positive Post-op RT 50 Gy in 25 fractions Phase 2 to 66 Gy, all cases CTOS 2004 Phase 1:5 cm longitudinal 2 cm axial Phase 2: 2 cm coverage

3 SR-2 Trial Trial open from late 1994 to late 1997Trial open from late 1994 to late 1997 190 patients entered from 10 Canadian centres190 patients entered from 10 Canadian centres Sample size to detect 15% difference in wound complications (80% power)Sample size to detect 15% difference in wound complications (80% power) Closed after a planned interim analysis showed significant difference between two arms for the primary end-point, and no value in continuing after primary question addressedClosed after a planned interim analysis showed significant difference between two arms for the primary end-point, and no value in continuing after primary question addressed CTOS 2004

4 Previous Analyses (3.3 years Median FU) Primary End-point (wound complications)Primary End-point (wound complications) –Twice the rate in pre vs post-op (35 vs 17%) –Confined to the lower extremity Secondary End-pointsSecondary End-points –QoL and function similar after 1 year –Survival advantage favoring pre-op RT O’Sullivan et al, Lancet 2002 Davis et al, JCO 2002 Background

5 SR-2 Local Control and Survival: First analysis (3.3 yrs median follow up) Lancet 2002;359:2235-2241 Background

6 Pre-opPost-opTotal n (%)n (%) n (%) Total94(100)96(100) 190(100) Gender:Female42 (45) 44(46)86(45) Male52(55)52 (54)104(55) Age:<50 32 (34) 45(47)77(41) ≥50<70 39 (42)34 (36)73(38) ≥70 23 (24)17 (18)40(21) PresentationPrimary83(88)89(93)172(91) Recurrent11(12)7(7)18(9) Patient Characteristics CTOS 2004 (Analysis: Dec 2003) Median Follow-up: 6.9 years (range 0 – 8.6 years)

7 Pre-opPost-opTotal n (%)n (%) n (%) Total94(100)96(100) 190(100) Size:≤ 10 cm 61 (65) 64(67)125(66) (stratification)> 10 cm33(35)32 (33)65(34) Grade:Low 15 (16) 17(18)32(17) Interm / High 79 (84)79 (82)158(83) HistologyMFH29(31)23(24)52(27) Liposarc.26(28)26(27)52(27) Leiomyos.10(11)9(9)19(10) Other29(31)38(40)67(35) Tumor Characteristics CTOS 2004 (Analysis: Dec 2003)

8 Pre-opPost-opTotal n (%)n (%) n (%) Total94(100)96(100) 190(100) Compartment:Intracompartment 48 (51) 50(52)100(52) Extra – by growth29(31)26 (27)55(29) Extra - iatrogenic12(13)11 (11)23(12) Extra - de novo 5(5) 9 (9)14(7) Depth:Deep to fascia56 (59) 48(50)104(55) Deep & Superficial 23 (24)28 (29)51(27) Superficial15(16)20(21)35(18) Site *Upper:Proximal 11(12)12(13)23(12) Distal 10(11)8(8)20(11) Lower: Proximal 47(50)56(58)103(54) Distal 26(28)20(21)46(24) Resection marginsPositive14(15)13(13)27(14) Negative80(85)83(87)163(86) * Distal upper includes elbow; Proximal lower includes knee Anatomic Characteristics

9 Pre-op Post-opTotal n %n%n% Alive64(68)62(65)126 (66.3) Dead30(32)34(35)64(33.7) Cause of death: Disease24(80)26(76)50 (78) Non-protocol complication0(0)1(3)1(2) Other4(13)4(12)8(12) Other primary cancer2(7)3(9)5(8) Total94(100)96(100)190 (100) Patient status at last follow-up CTOS 2004 (Analysis: Dec 2003)

10 Pre-opPost-op N = 94N = 96 Compartment:Intracompartment 92.9% 97.9% Extra-compartmental93.0%85.7% Depth:Superficial 100.0% 95.0% Deep 91.5% 91.6% Anatomic Site Upper Limb 95.2% 94.7% Lower Limb 92.3% 91.7% Tumor Size <=10 cm 98.1% 92.1% >10 cm 83.6% 92.6% GradeLow86.7% 100% High94.5% 90.5% 5 year local control by Tumor Characteristics

11 Environmental / Treatment 5 year local control by prognostic factors Pre-opPost-op N = 94N = 96 Resection Margins95.8% 95.0% 77.1% 73.3% Treatment Center:PMH 91.7% 92.0% Other94.4%92.7% Presentation:Primary 93.4% 91.7% Recurrent 90.0% 100.0% Age <50 93.0% 97.7% >=5093.0% 87.2% GenderMale95.4% 96.0% Female90.0% 87.9% Pre-opPost-op N = 94N = 96 Resection MarginsNegative95.8% 95.0% Positive77.1% 73.3% Treatment Center:PMH 91.7% 92.0% Other94.4%92.7% Presentation:Primary 93.4% 91.7% Recurrent 90.0% 100.0% Host Factors

12 HR of post-op to Log-rank pre-op with 95% CIp-value 1.2 (0.4-3.5)0.76 HR of post-op to Log-rank pre-op with 95% CIp-value 0.96 (0.6-1.6)0.86 HR of post-op to Log-rank pre-op with 95% CIp-value 1.0 (0.7-1.6)0.92 HR of post-op to Log-rank pre-op with 95% CIp-value 1.1 (0.7-2.0)0.64 Local recurrence freeRegional / distant recurrence free Progression free survivalDisease specific survival

13 Cox regression models with P-Values for Risk Ratios (not shown) for outcomes LocalMetProgressDiseaseOverall Predictor RecRecFree survSpec SurvSurvival Pre vs Post0.561.000.790.490.32 Center (PMH vs other)0.630.940.730.810.22 Upper vs Lower Limb0.920.820.830.900.24 Grade (low vs high)0.520.010.0050.020.008 Max Baseline tumor size 0.110.020.100.00050.0002 Depth (superficial vs deep)0.630.570.910.340.62 Primary vs Recurrent Pres.0.880.500.730.940.98 Margins (‘pos’ vs ‘neg’)0.01NA0.10NANA CTOS 2004 (Analysis: Dec 2003) NA: not applicable (not included in model)

14 HR of post-op to Log-rank pre-op with 95% CIp-value 1.2 (0.7-2.0)0.48 ASCO 2004 (Analysis: Dec 2003) Overall survival

15 Late Subcutaneous Fibrosis (RTOG/EORTC) Grade 0NoneGrade 0None Grade 2slight induration (fibrosis) and loss of subcutaneous fatGrade 2slight induration (fibrosis) and loss of subcutaneous fat Grade 3severe induration and loss of subcutaneous tissue; field contracture >10% linear measurementGrade 3severe induration and loss of subcutaneous tissue; field contracture >10% linear measurement Grade 4necrosisGrade 4necrosis

16 Probability: 3-yr5-yr Pre-op:20%23% Post-op:26%36% P=0.02, log rank for equality of groups CTOS 2004 (Analysis: Dec 2003) Grade 3 or 4 subcutaneous fibrosis

17 Cox regression model for Grade 3 and 4 fibrosis Hazard 95% Hazard RatioP-Value Variable Ratio Confidence Limits Schedule (pre vs. post-op) 1.084 0.513, 2.2910.8325 Centre (PMH vs. other) 0.711 0.406, 1.248 0.2350 D max (total dose) 1.037 0.989, 1.0870.1316 Phase I field size (cm 2) 1.002 1.001, 1.003 0.0006 CTOS 2004 (Analysis: Dec 2003)

18 Summary and Conclusions No differences in cancer-specific outcomes between Pre-op vs. Post- op RT with the protocols used in this RCTNo differences in cancer-specific outcomes between Pre-op vs. Post- op RT with the protocols used in this RCT Very high local control rates (95 % range) are evident with combined Surgery and RT in extremity STSVery high local control rates (95 % range) are evident with combined Surgery and RT in extremity STS Morbidity profiles differ between both approaches:Morbidity profiles differ between both approaches: –Acute complications: significantly greater in pre-op (recoverable) –Late tissue effects: significantly greater in post-op (likely permanent) Local anatomic factors and wound reconstruction should dictate the choice of radiotherapy scheduleLocal anatomic factors and wound reconstruction should dictate the choice of radiotherapy schedule New local control techniques or approaches are needed to ameliorate local tissue toxicity (especially fibrosis, and bone later)New local control techniques or approaches are needed to ameliorate local tissue toxicity (especially fibrosis, and bone later) CTOS 2004 (Analysis: Dec 2003)

19 HR of post-op to Log-rank pre-op with 95% CIp-value 1.2 (0.7-2.0)0.48 ASCO 2004 (Analysis: Dec 2003) Overall survival

20 HR of post-op to Log-rank pre-op with 95% CIp-value 1.2 (0.7-2.0)0.48 ASCO 2004 (Analysis: Dec 2003) Overall survival

21 HR of post-op to Log-rank pre-op with 95% CIp-value 1.2 (0.7-2.0)0.48 ASCO 2004 (Analysis: Dec 2003) Overall survival ?

22 Brian O’Sullivan, a.k.a. “the Enforcer”, Toronto Maple Leafs, c. 1966-67 1931-32 1941-42 1944-45 1946-47 1947-48 1948-49 1950-51 1961-62 1962-63 1963-64 1966-67

23

24 Cox regression model for Local Control Predictor p-value Risk Ratio95% CI for Risk Ratio Pre vs Post0.560.72(0.23,2.2) Centre (PMH vs other)0.631.33(0.41,4.27) Upper vs Lower Limb0.921.08(0.22,5.25) Grade (low vs high)0.520.60(0.13,2.79) Max Baseline tumor size 0.111.02(1.00,1.06) Depth (superficial vs deep)0.630.60(0.07,4.89) Primary vs Recurrent Pres.0.881.18(0.15,4.54) Margins (‘pos’ vs ‘neg’)0.014.66(1.38,15.7) CTOS 2004 (Analysis: Dec 2003)

Download ppt "Five year results of a randomized Phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma Brian O'Sullivan, Aileen."

Similar presentations

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
CARBON ION THERAPY FOR SACRAL CHORDOMAS

CARBON ION THERAPY FOR SACRAL CHORDOMAS
IMRT, Designed with Evidence-Based Bone Avoidance Objectives, Reduces the risk of Bone Fracture in the management of Extremity Soft Tissue Sarcoma Colleen.

IMRT, Designed with Evidence-Based Bone Avoidance Objectives, Reduces the risk of Bone Fracture in the management of Extremity Soft Tissue Sarcoma Colleen.
CTOS, Boca Raton, 2005 A Radiation Treatment Planning Comparison for Lower Extremity Soft Tissue Sarcoma: Can the Future Surgical Wound Be Spared? Anthony.

CTOS, Boca Raton, 2005 A Radiation Treatment Planning Comparison for Lower Extremity Soft Tissue Sarcoma: Can the Future Surgical Wound Be Spared? Anthony.
In-Depth Analysis of Wound Complications Following Preoperative Radiotherapy for Lower Extremity Soft Tissue Sarcoma Patients Colleen Dickie MSc, MRT(T)(MR)

In-Depth Analysis of Wound Complications Following Preoperative Radiotherapy for Lower Extremity Soft Tissue Sarcoma Patients Colleen Dickie MSc, MRT(T)(MR)
Primary thoracic sarcomas: prognostic factors and outcome in a series of patients treated at a single institution Leonardo Duranti T horacic Surgery.

Primary thoracic sarcomas: prognostic factors and outcome in a series of patients treated at a single institution Leonardo Duranti T horacic Surgery.
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)

IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
San Antonio Breast Cancer Symposium 2007 Highlights – Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford.

San Antonio Breast Cancer Symposium 2007 Highlights – Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford.
Anal Cancer Rob Glynne-Jones Mount Vernon Cancer Centre on behalf of NCRI anal cancer subgroup.

Anal Cancer Rob Glynne-Jones Mount Vernon Cancer Centre on behalf of NCRI anal cancer subgroup.
IMRT vs. BRACHYTHERAPY FOR SOFT TISSUE SARCOMA. EXTERNAL RT IN STS NCI Trial (Yang JC et al, JCO 1998) Extremity / Superficial Trunk STS (n=141) LSS Alone.

IMRT vs. BRACHYTHERAPY FOR SOFT TISSUE SARCOMA. EXTERNAL RT IN STS NCI Trial (Yang JC et al, JCO 1998) Extremity / Superficial Trunk STS (n=141) LSS Alone.
LOCAL CONTROL AMONG YOUNG PATIENTS WITH NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA (NRSTS) FOLLOWING RISK-BASED TREATMENT: RESULTS FROM CHILDREN’S ONCOLOGY.

LOCAL CONTROL AMONG YOUNG PATIENTS WITH NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA (NRSTS) FOLLOWING RISK-BASED TREATMENT: RESULTS FROM CHILDREN’S ONCOLOGY.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.

Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Hot topics in breast radiotherapy Mark Beresford.

Hot topics in breast radiotherapy Mark Beresford.
Thomas F. DeLaney MD, Aashish D. Bhatt MD, Alex Jacobson BS, Richard Y. Lee MD, PhD, Christine Giraud BS, Joseph H. Schwab MD, MS, Francis J. Hornicek.

Thomas F. DeLaney MD, Aashish D. Bhatt MD, Alex Jacobson BS, Richard Y. Lee MD, PhD, Christine Giraud BS, Joseph H. Schwab MD, MS, Francis J. Hornicek.
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;

PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
Pulmonary Metastasis From Osteosarcoma Multi-factorial analysis of survival at first lung involvement Ali Aljubran, Martin Blackstein for the University.

Pulmonary Metastasis From Osteosarcoma Multi-factorial analysis of survival at first lung involvement Ali Aljubran, Martin Blackstein for the University.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.

Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
Margin Reduction using IGRT For Soft-Tissue Sarcoma: Secondary Analysis of RTOG 0630 Dian Wang, MD., Ph.D. Rush University Medical Center CTOS October.

Margin Reduction using IGRT For Soft-Tissue Sarcoma: Secondary Analysis of RTOG 0630 Dian Wang, MD., Ph.D. Rush University Medical Center CTOS October.
CTOS 2013 Radiation Oncology Session Discussion Elizabeth H Baldini, MD, MPH Associate Professor of Radiation Oncology Harvard Medical School Brigham and.

CTOS 2013 Radiation Oncology Session Discussion Elizabeth H Baldini, MD, MPH Associate Professor of Radiation Oncology Harvard Medical School Brigham and.

Similar presentations

Ads by Google